REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis

... Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced theEuropean Commission has granted approval of REMICADE(R) (infliximab) for thetreatment of moderately to severely active ulcerative colitis (UC) in patientswho have had an inadequate response to conventional therapy, includingcorticosteroids and 6-MP or AZA, or who are intolerant to or have medicalcontraindications for such therapies... click link for more info. ...